A Randomized controlled Clinical Trial to determine the efficacy of Siddha drugs in COVID 19 patients
Phase 2
Completed
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
- Registration Number
- CTRI/2020/06/025763
- Lead Sponsor
- ational institute of Siddha
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Male, Female and Transgenders.
ï?· Age between 18 to 85 years
ï?· COVID 19 positive asymptomatic / pre symptomatic, mild and moderately and severely symptomatic patients.
ï?· Willing to consent to the study.
Exclusion Criteria
High risk groups (Patients with Complications of Diabetes, Heart diseases, Cancer and Pregnancy)
ï?· Multi organ failure Syndrome (MODS).
ï?· Patients participating in other COVID 19 trials.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary Outcome would be measured through Reduction of symptoms and <br/ ><br>Recovery of patients from COVID 19 disease in a time bound manner.Conversion of RT PCR negative within first week of accelerated recoveryTimepoint: 6 months
- Secondary Outcome Measures
Name Time Method Possible reduction of viral load data in subjects both at baseline and at 7 days, and 14 days or at recovery or 30 days whichever is earlier.. <br/ ><br>ï?· Number of days on treatment before recovery and Case fatality rate will also be noted. <br/ ><br>ï?· Reduction in Signs and symptoms like Fever, cough, breathlessness, and improvement in O2 saturation (SpO2) and PaO2/FiO2 becoming 300mg/Hg in patients with severe grade and ARDS.Timepoint: 6 MONTHS